PL1708722T3 - Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza - Google Patents

Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza

Info

Publication number
PL1708722T3
PL1708722T3 PL05712839T PL05712839T PL1708722T3 PL 1708722 T3 PL1708722 T3 PL 1708722T3 PL 05712839 T PL05712839 T PL 05712839T PL 05712839 T PL05712839 T PL 05712839T PL 1708722 T3 PL1708722 T3 PL 1708722T3
Authority
PL
Poland
Prior art keywords
therapy
interstitial
novel
symptom relief
chronic
Prior art date
Application number
PL05712839T
Other languages
English (en)
Polish (pl)
Inventor
C Lowell Parsons
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34826198&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1708722(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PL1708722T3 publication Critical patent/PL1708722T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL05712839T 2004-01-28 2005-01-27 Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza PL1708722T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54018604P 2004-01-28 2004-01-28
PCT/US2005/003542 WO2005072751A1 (en) 2004-01-28 2005-01-27 Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
EP05712839.9A EP1708722B1 (de) 2004-01-28 2005-01-27 Neuartige interstitielle therapie zur sofortigen linderung von symptomen und langzeittherapie bei interstitieller zystitis

Publications (1)

Publication Number Publication Date
PL1708722T3 true PL1708722T3 (pl) 2014-10-31

Family

ID=34826198

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05712839T PL1708722T3 (pl) 2004-01-28 2005-01-27 Nowa śródmiąższowa terapia dla natychmiastowego złagodzenia objawów i przewlekła terapia śródmiąższowego zapalenia pęcherza

Country Status (10)

Country Link
US (4) US7414039B2 (de)
EP (2) EP2813231A1 (de)
AU (1) AU2005209322B2 (de)
CA (1) CA2554489A1 (de)
DK (1) DK1708722T3 (de)
ES (1) ES2493626T3 (de)
PL (1) PL1708722T3 (de)
PT (1) PT1708722E (de)
SI (1) SI1708722T1 (de)
WO (1) WO2005072751A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142208A1 (en) 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
DK2839830T3 (da) * 2005-01-14 2019-08-19 Urigen Inc Kits og sammensætninger til behandling af lidelser i de nedre urinveje
CA2618349C (en) 2005-08-11 2016-05-31 Massachusetts Institute Of Technology Intravesical drug delivery device and method
US20070172508A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
EP2607477B1 (de) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
US8574567B2 (en) * 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8828452B2 (en) * 2007-05-22 2014-09-09 Glenn Abrahmsohn Method for pain control
ES2481454T3 (es) * 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
EP2328628A2 (de) 2008-08-09 2011-06-08 Massachusetts Institute of Technology Implantierbare arzneiabgabevorrichtung und verfahren zur behandlung von urogenital- und umliegendem gewebe beim mann
FR2938187B1 (fr) † 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
US8637577B2 (en) 2009-01-22 2014-01-28 Absorption Pharmaceuticals, LLC Desensitizing drug product
EP2445571B1 (de) * 2009-06-26 2012-11-21 Taris Biomedical, Inc. Feste wirkstofftabletten für implantierbare wirkstofffreisetzungsvorrichtungen
US9107885B2 (en) * 2009-08-13 2015-08-18 Lubris Llc PRG4 treatment for interstitial cystitis
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
WO2011057133A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Fragmented hydrogels
AU2011213175A1 (en) * 2010-02-04 2014-02-20 Michael M. Goldberg Use of oral heparin preparations to treat urinary tract diseases and conditions
ES2822118T3 (es) 2010-08-05 2021-04-29 Taris Biomedical Llc Dispositivos de administración de fármacos implantables para sitios genitourinarios
WO2012094515A1 (en) * 2011-01-06 2012-07-12 Parsons C Lowell Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
RU2620032C2 (ru) 2011-01-10 2017-05-22 Аллерган, Инк. Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании
US9107816B2 (en) 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
US9849086B2 (en) 2012-03-19 2017-12-26 Nanologix Research, Inc. Method and composition for treating cystitis
WO2014171986A1 (en) * 2013-01-28 2014-10-23 Urigen Pharmaceuticals, Inc. Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer
SG10201708522SA (en) 2013-03-15 2017-12-28 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
ES2956840T3 (es) 2013-08-19 2023-12-29 Taris Biomedical Llc Dispositivos de administración de fármacos de múltiples unidades
CA2949480A1 (en) * 2014-02-24 2015-08-27 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
RU2586285C1 (ru) * 2015-03-24 2016-06-10 Общество с ограниченной ответственностью "ФармСинергия" Водная композиция для инстилляций в мочевой пузырь
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
MX2019012272A (es) * 2017-04-12 2020-07-28 Urigen Pharmaceuticals Inc Artículo de fabricación que comprende anestésico local, regulador de ph y glicosaminoglicano en jeringa con estabilidad mejorada.
RU2648443C1 (ru) * 2017-05-10 2018-03-26 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) Способ профилактики обострения посткоитального цистита
PL3958873T3 (pl) 2019-04-26 2024-04-15 Tcm Biotech International Corp. Kompozycja farmaceutyczna do zapobiegania nawracającemu zakażeniu dróg moczowych
WO2021009525A1 (en) * 2019-07-18 2021-01-21 Lovasz Sandor Medicinal and/or pharmaceutical compositions for intravesical instillation, preparation and use thereof
AU2020315353A1 (en) * 2019-07-18 2022-03-10 C. Lowell Parsons Alkalization of urinary bladder wall prior to treatment with intravesical heparin and alkalinized lidocaine to enhance relief of bladder pain symptoms
HUP2000144A1 (hu) * 2020-04-29 2022-04-28 Lovasz Sandor Dr Vizelet lúgosító gyógyászati és/vagy gyógyszerkészítmény interstitialis cystitis / hólyagfájdalom szindróma (IC/BPS)orális kezelésére és formulálása

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268518A (en) * 1979-05-19 1981-05-19 Fisons Limited Method of treating cystitis
US4460360A (en) 1982-08-30 1984-07-17 Finegold Aaron N Urethral anesthetic devices
US5037810A (en) 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
US4879282A (en) 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US5196405A (en) 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
US5104856A (en) * 1990-11-09 1992-04-14 Uab Research Foundation Heparan sulfate biosynthesis primers
US5137528A (en) 1990-11-26 1992-08-11 Crose Virginia W Ampoule for administering a liquid local anaesthetic
WO1993002653A1 (en) * 1991-08-08 1993-02-18 Segel Leigh D Fluorocarbon blood substitute
GB9310095D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
ZA962455B (en) * 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
BR9710241A (pt) 1996-07-11 1999-08-10 Farmarc Nederland Bv Comprexo de inclusao que contem agonista de serotonina seletivo a indol
US5879282A (en) * 1997-01-21 1999-03-09 Cordis A Johnson And Johnson Company Catheter having an expandable radioactive source
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6083933A (en) 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
RU2147876C1 (ru) * 1999-07-08 2000-04-27 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Фармацевтическая композиция для обезболивания в офтальмологии
US6740333B2 (en) 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6648863B2 (en) 2000-09-20 2003-11-18 Scimed Life Systems, Inc. Apparatus and methods for treating the urinary bladder
JP4822652B2 (ja) 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
WO2002045705A2 (en) * 2000-12-08 2002-06-13 Pieter Theo Ernst Regenaration of blood vessels
US20040142968A1 (en) 2003-01-17 2004-07-22 Donald Price Method and kit for treating lower bowel pain
WO2004066990A2 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040161476A1 (en) * 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US20040248979A1 (en) 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DK2839830T3 (da) * 2005-01-14 2019-08-19 Urigen Inc Kits og sammensætninger til behandling af lidelser i de nedre urinveje

Also Published As

Publication number Publication date
DK1708722T3 (da) 2014-08-25
WO2005072751A1 (en) 2005-08-11
AU2005209322A1 (en) 2005-08-11
CA2554489A1 (en) 2005-08-11
US20170007638A1 (en) 2017-01-12
US20190321391A1 (en) 2019-10-24
EP1708722A1 (de) 2006-10-11
PT1708722E (pt) 2014-09-12
ES2493626T3 (es) 2014-09-12
US7414039B2 (en) 2008-08-19
US9486474B2 (en) 2016-11-08
EP1708722B1 (de) 2014-05-21
AU2005209322B2 (en) 2011-05-19
US20080300219A1 (en) 2008-12-04
EP2813231A1 (de) 2014-12-17
SI1708722T1 (sl) 2014-10-30
US20050234013A1 (en) 2005-10-20
EP1708722A4 (de) 2009-04-01

Similar Documents

Publication Publication Date Title
EP1708722A4 (de) Neuartige interstitielle therapie zur sofortigen linderung von symptomen und langzeittherapie bei interstitieller zystitis
IL180759A0 (en) Indazoles useful in treating cardiovascular diseases
HK1136822A1 (en) Therapeutic compounds and their use in cancer
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
GB0416857D0 (en) Electronic financial transactions
EP1711191A4 (de) Chlorit bei der behandlung neurodegenerativer krankheiten
GB0523576D0 (en) Drug composition and its use in therapy
GB0400700D0 (en) Compounds useful in therapy
GB0607946D0 (en) Mono and combination therapy
HK1114882A1 (en) Retrotransposon inhibition in therapy
GB0607949D0 (en) Mono and combination therapy
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1827417A4 (de) Photodynamische therapie mit verbesserter okklusiver wirkung
GB0428170D0 (en) Mono and Combination Therapy
IL193663A0 (en) Thiadiazole compounds and their use in phototherapy
GB2417688B (en) Improvements in and relating to neurostimulation
GB2434547B (en) Improvements in and relating to peripheral neurostimulation
EP1810673A4 (de) Therapeutisches mittel für interstitielle cystitis
GB0425854D0 (en) Therapeutic treatment
GB0700827D0 (en) Hai-1 and Hai-2 in cancer therapy
EP1874280A4 (de) Topische behandlung mit ngf und dha in geschädigter hornhaut
GB0512551D0 (en) Methods and therapeutic treatments
GB0408752D0 (en) Therapeutic treatment
GB0401384D0 (en) Compounds useful in therapy
GB0416876D0 (en) Compound and use in treatment